ASAP Case Challenge Volume 1
Confirm the Diagnosis. Choose the Right Therapy.
Work through 72 case-based questions focused on two core skills: confirming an endocrine diagnosis with the right test and choosing the right therapy. Cases cover primary aldosteronism and adrenal venous sampling, osteoporosis treatment sequencing, GLP-1 receptor agonists and SGLT2 inhibitors across comorbidities, hyperprolactinemia, and surgery and TSH targets in thyroid cancer.
Course overview
Volume 1 focuses on the decisions at the start of care: which test confirms the diagnosis, and which therapy best fits the patient in front of you. Cases ask you to choose a confirmatory test, match a treatment to a patient’s comorbidities, and weigh how strong the evidence behind a recommendation is.
Tracks you’ll explore
- Adrenal & Pituitary: Adrenal venous sampling and MRA dosing in primary aldosteronism; confirming ACTH-independent cortisol secretion; imaging risk stratification of adrenal masses; methoxytyramine in SDHB carriers; the desmopressin test for pseudo-Cushing states; oral octreotide monitoring; and MEN1 and pituitary microadenoma surveillance.
- Calcium & Bone: Treatment choices in glucocorticoid-induced osteoporosis and after a recent fracture; sequential therapy after denosumab; atypical femoral fracture; parathyroidectomy and normocalcemic hyperparathyroidism; hypoparathyroidism after thyroidectomy and PTH replacement; CYP24A1-related hypercalcemia in pregnancy; and genetic evaluation of early-onset osteoporosis.
- Diabetes & Hypoglycemia: Choosing GLP-1 receptor agonists and SGLT2 inhibitors in MASH, HFpEF, CKD, type 1 diabetes, and gallbladder disease; interpreting CGM time in range; automated insulin delivery in type 1 diabetes; peripheral artery disease screening with noncompressible vessels; and sexual health in men with diabetes.
- Lipids, Obesity & Nutrition: apoB and LDL-C discordance; bempedoic acid; continuing semaglutide and managing its tolerability; distinguishing familial from multifactorial chylomicronemia; choosing a bariatric procedure; pregnancy after gastric bypass; intermittent fasting, sweeteners, and active video games; and diabetic gustatory sweating.
- Reproduction: Functional hypothalamic amenorrhea; selecting candidates for menopausal hormone therapy; monitoring testosterone therapy; long-term monitoring during feminizing hormone therapy; testosterone cost and hair loss in transgender men; and separating drug-induced hyperprolactinemia from prolactinoma.
- Thyroid: Lobectomy versus total thyroidectomy and how to read the evidence behind that choice; quality of life after thyroid surgery; TSH targets and the risks of suppression; 2025 ATA risk stratification; active surveillance for microcarcinoma; combined T4 and T3 therapy; and subclinical hypothyroidism in heart failure.
Course details
- Format: 72 case-based questions: 12 in each of six specialty tracks
- Credit: Up to 6.0 AMA PRA Category 1 Credits™ and 6.0 ABIM MOC points for completing all six specialty tracks in the volume
- Pricing: Nonmember: $295 | Informed Member: $235 | Engaged Member: $175 | Fellow, Resident, Student Member: $145
- Access: On demand through the AACE Learning App for iOS and Android, with offline access and progress that syncs across devices
- Release date: 9/14/2026 - 9/14/2029
- Intended audience: Clinical Endocrinologists
9/14/2026
9/14/2029
After completing this course, learners should be better able to:
- Select appropriate confirmatory and second-line tests for adrenal, pituitary, parathyroid, and lipid disorders.
- Choose diabetes, obesity, and osteoporosis therapies that match a patient’s comorbidities and fracture or cardiovascular risk.
- Apply the 2025 ATA risk stratification system and evidence on the extent of surgery to thyroid cancer management.
- Critically appraise the evidence behind common endocrine treatment recommendations.
This program is intended for clinical endocrinologists.
Meet the ASAP Faculty
Learn about the endocrine experts who develop and lead ASAP Microlearning Volumes and Case Challenges.